The Science of Hope: 5 European Innovators Redefining What's Possible in Parkinson's Disease

That is the defining challenge of Parkinson's research today. And on World Parkinson's Day, it's worth taking a clear-eyed look at how close European science is getting to changing it and what it will take, in people as much as in compounds, to get there.

For decades, Parkinson's treatment has been built around symptom management. Dopamine replacement therapies have given millions of people more functional years. But they don't slow down what's happening underneath.

The field is now at a genuine turning point. The question driving most of the serious investment today is whether we can modify the disease itself, whether it's possible to intervene at the biological level and slow, or even halt, neurodegeneration before it accumulates irreversibly.

Alpha-synuclein has emerged as the leading target. This protein, which misfolds and aggregates in the brains of Parkinson's patients, is now the focus of antibody therapies, vaccines, and small-molecule approaches at multiple stages of clinical development. Biomarkers are quietly transforming how trials are designed, enabling earlier detection and more precise patient stratification. AI is accelerating target discovery. And genetic research is opening precision medicine pathways, particularly around LRRK2 and GBA mutations that were inaccessible just a few years ago.

There are now two Phase III drugs targeting alpha-synuclein that could become landmark approvals in this space. That alone marks a meaningful shift in what the field believes is achievable.

Roche (Switzerland)

Roche has committed to Phase 3 development of prasinezumab, an anti-alpha-synuclein antibody developed with Prothena, citing encouraging efficacy signals from earlier trials. The ongoing Phase 3 PARAISO study uses a time-to-event primary endpoint focused on confirmed motor progression, a more clinically meaningful measure than that used in previous trials. Five-year data from the Phase II PASADENA trial, presented at AD/PD 2026, showed sustained slowing of motor and functional decline compared to an external comparator group, supporting the potential disease-modifying properties of prasinezumab. The stakes are high: Roche has stated that prasinezumab could be the first disease-modifying treatment for a condition affecting 10 million people worldwide, with peak sales potential greater than $3 billion.

UCB (Belgium)

UCB is pursuing Parkinson's on two fronts simultaneously. Its investigational anti-alpha-synuclein antibody UCB7853 targets the extracellular spread of the protein, the mechanism believed to drive neurodegeneration between cells. Glovadalen, an orally available, brain-penetrant small molecule under investigation for Parkinson's disease, reported positive Phase 2a results, with UCB assessing next steps and exploring opportunities across neurological conditions associated with dopamine deficiency. UCB's parallel pursuit of both symptom management and disease modification reflects a mature understanding of what patients actually need across their disease journey.

AC Immune (Switzerland)

AC Immune is one of the most closely watched European biotechs in neurodegeneration right now. In December 2025, the company reported positive interim Phase 2 data from its Parkinson's vaccine, designed to trigger antibodies that break up and stop the spread of toxic alpha-synuclein aggregates, results that AC Immune described as the first evidence that active immunotherapy could slow the progression of Parkinson's disease. Interim data showed the therapy triggering the desired immune response, with biological markers and clinical measures of motor function suggesting it may also be stabilising disease, including neurofilament light chain levels, a key biomarker of nerve cell damage, remaining steady in the vaccine arms while increasing in the placebo group. For a field accustomed to setbacks, this was a meaningful signal.

Asceneuron (Switzerland)

Asceneuron takes a different mechanistic approach. Rather than targeting alpha-synuclein directly, the company develops small-molecule OGA inhibitors that act intracellularly, preventing the aggregation of both tau and alpha-synuclein by stabilising their glycosylated forms. Their lead asset, ASN51, has demonstrated full CNS uptake and high enzyme occupancy across multiple Phase 1 trials, with Phase 2 development now underway for Alzheimer's disease and broader neurodegenerative applications, including Parkinson's. The oral, once-daily formulation is a practical advantage in a field where most advanced candidates require infusion, and the multimodal mechanism positions Asceneuron as a potential combination-therapy partner as the landscape matures.

VectorY Therapeutics (Netherlands)

VectorY is an Amsterdam-based biotech founded with a mission to develop vectorised antibody treatments for people with neurodegenerative diseases, combining highly selective therapeutic antibodies with one-time AAV-based delivery to the CNS, with a pipeline spanning ALS, Huntington's, and Parkinson's disease. In September 2025, VectorY entered an option and license agreement with Shape Therapeutics to advance its pipeline of neurodegenerative disease programmes using a deep-brain-penetrant AAV capsid, with its lead programme, VTx-002, in ALS, progressing toward clinical development in early 2026. The vectorised antibody platform delivering a one-time gene therapy that produces sustained antibody levels in the CNS represents a genuinely novel approach for diseases where repeated dosing has historically proven inadequate. VectorY's Parkinson's programme remains in preclinical development, but the Amsterdam Science Park team is building the platform and manufacturing capability that underpins it.

Innovation at this pace creates a different kind of pressure, one that doesn't show up in pipeline reports, but shapes whether compounds reach patients on time.

In our experience working across European life sciences, demand for neurodegeneration talent has shifted considerably over the last two years. Clinical development professionals with CNS trial expertise are genuinely scarce. Regulatory specialists who understand the evolving EMA framework for neurodegenerative disease, including requirements around biomarker-defined patient populations, are being sought by multiple organisations simultaneously. And the growing use of gene therapy platforms across the Netherlands and Switzerland is creating acute demand for AAV process development, analytical development, and QA professionals who understand both the science and the GMP environment in which they operate.

We see a growing demand for professionals at the intersection of clinical operations and translational biomarker strategy, people who understand what it means to run an adaptive trial with a novel primary endpoint in a highly complex patient population. That profile is rare, and competition for it is intensifying as more programmes across Switzerland, Belgium, and the Netherlands enter mid and late-stage development.

The Leiden Bio Science Park, Amsterdam Science Park, and Basel cluster are all drawing from the same constrained talent pool. Organisations that move early with genuine clarity about the profiles they need consistently have better options than those waiting until urgency forces their hand.

The next five years in Parkinson's research will be defined by whether the current generation of disease-modifying candidates can deliver in Phase 3 what Phase 2 has suggested. If prasinezumab, AC Immune's vaccine, or other advanced programmes achieve their endpoints, it would mark the first time a therapy has meaningfully altered the course of this disease, not just managed its symptoms.

That outcome won't be determined by science alone. It will be shaped by the quality of the clinical teams running the trials, the regulatory professionals guiding submissions, and the operational leaders keeping programmes on track under real-world pressure.
For hiring managers building neurodegeneration capabilities: the window to attract the right people is earlier than it feels. The talent market in this space is already constrained, and it is tightening. For professionals with a background in CNS, gene therapy, clinical development, or regulatory affairs: the opportunity to contribute to one of the most consequential areas of medicine is genuine, and it is now.

At Panda, we support life sciences organisations across Europe including in the Netherlands, Switzerland, Belgium, and Germany in building the specialist teams that translate scientific ambition into patient impact. If you're working in neurodegeneration and want to understand what the talent market looks like right now, we're always open to a conversation.